Semaglutide and GLP-1 Drugs for Fatty Liver (MASH): What the Evidence Shows in 2026

Semaglutide 2.4 mg weekly is now approved in India (CDSCO, July 2026) and the US (FDA, August 2025) for adults with non-cirrhotic MASH and moderate-to-advanced (F2–F3) fibrosis, alongside diet and exercise. In the ESSENCE trial, steatohepatitis resolved in 62.9% on semaglutide versus 34.3% on placebo, and fibrosis improved in 36.8% versus 22.4%. It is not approved for cirrhosis.
— Dr Chetan Kalal, DM Hepatology, Gleneagles Hospital Mumbai

A 48-year-old chartered accountant from Pune arrives with a FibroScan report folded in his pocket: liver stiffness 11 kPa, a CAP score showing heavy fat, HbA1c 7.6, and a question he has already asked three doctors. “My colleague is on the weight-loss injection. Will it fix my liver?” Two years ago the honest answer was “we don’t know”. In 2026 the answer is more interesting — and more specific than the advertisements suggest. (This is an illustrative scenario, not a specific patient.)

Fatty liver disease is now the commonest liver problem I see in Mumbai, and the patients are getting younger. Most have simple fat and need lifestyle change, not drugs. A minority have MASH with fibrosis, the stage at which the liver is actively scarring and the risk of cirrhosis, liver cancer and heart disease climbs. For that group, the arrival of approved medicines is a genuine shift. This guide explains who qualifies, what the trials actually showed, and where the limits are.

Disclosure: I serve on advisory panels for Novo Nordisk (maker of semaglutide, sponsor of the ESSENCE trial) and Eli Lilly (maker of tirzepatide, sponsor of SYNERGY-NASH). I have tried to present the data, including its limitations, exactly as published; the references below let you check every number.

MASLD, MASH and fibrosis: who actually needs a drug?

The names changed in 2023. What used to be called NAFLD is now MASLD — metabolic dysfunction-associated steatotic liver disease — fat in the liver with at least one metabolic risk factor such as excess weight, diabetes, high blood pressure or abnormal cholesterol. MASH is the subset in which that fat causes inflammation and liver-cell injury. Fibrosis is the scar tissue that injury lays down, staged from F0 (none) to F4 (cirrhosis).

The single most important number in your liver work-up is the fibrosis stage. Fat alone, however much the ultrasound report emphasises “grade 2” or “grade 3”, does not by itself decide outcome. Fibrosis does. That is why the European EASL-EASD-EASO guidelines of 2024 build the whole pathway around non-invasive fibrosis assessment — a blood-based score such as FIB-4 first, then FibroScan or MR elastography when needed, and liver biopsy only when the picture remains unclear.

The drug approvals follow the same logic. Semaglutide’s MASH approval in India and the US covers adults with non-cirrhotic MASH and moderate-to-advanced fibrosis, that is F2 or F3. It does not cover simple fatty liver with no fibrosis, where lifestyle change remains the treatment, and it does not cover cirrhosis, where the evidence is not yet in. If you have been told you have “fatty liver”, the first question to ask is not “which injection?” but “what is my fibrosis stage?” Our fatty liver clinic page explains how we stage it at Gleneagles.

What the ESSENCE trial showed

ESSENCE is the phase 3 trial on which the semaglutide approvals rest. It enrolled 1,197 adults with biopsy-proven MASH and F2–F3 fibrosis and randomised them two-to-one to once-weekly semaglutide 2.4 mg or placebo, for a planned 240 weeks. The results published in the New England Journal of Medicine in 2025 are from a planned interim analysis of the first 800 patients at week 72.

On the two primary end points, semaglutide clearly won. Steatohepatitis resolved without fibrosis worsening in 62.9% of semaglutide patients and 34.3% of placebo patients. Fibrosis improved by at least one stage without steatohepatitis worsening in 36.8% versus 22.4%. Both steatohepatitis resolution and fibrosis improvement together occurred in 32.7% versus 16.1%. Average weight loss was 10.5% against 2.0%.

Read those numbers carefully. The placebo group did surprisingly well — a third had steatohepatitis resolution, a fifth had fibrosis improvement — because everyone in a trial receives lifestyle counselling and closer follow-up. That is both a caveat and an encouragement: diet, exercise and diabetes control genuinely work. The drug adds to them; it does not replace them. Note too that these are biopsy end points at 72 weeks. Whether semaglutide reduces cirrhosis, liver cancer and liver-related death is what part 2 of ESSENCE is designed to show, and those outcome data are not yet available. The approvals are therefore accelerated or conditional in nature, granted on the strength of the histology.

The earlier phase 2 trial, with daily semaglutide in 320 patients, is a useful reminder of that gap: NASH resolution reached 59% at the highest dose versus 17% on placebo, but fibrosis improvement (43% vs 33%) was not significantly different. ESSENCE, larger and longer, did show a fibrosis benefit.

Tirzepatide, resmetirom and the other options

Tirzepatide, which acts on both GIP and GLP-1 receptors, produced striking phase 2 results in SYNERGY-NASH: among 190 participants with F2–F3 MASH, steatohepatitis resolved in 44%, 56% and 62% at the 5, 10 and 15 mg doses against 10% on placebo, and fibrosis improved in 51–55% against 30%. Phase 2 trials are small and short, though, and tirzepatide is not yet established as a MASH treatment.

Resmetirom works differently: it is an oral drug that acts directly on liver cells through the thyroid hormone receptor-β, without causing weight loss. In MAESTRO-NASH, 966 patients with F1B–F3 fibrosis were analysed; MASH resolved in 25.9–29.9% against 9.7%, and fibrosis improved in 24.2–25.9% against 14.2%. The US FDA approved it in March 2024. Its effect sizes look smaller than semaglutide’s, but cross-trial comparisons are unreliable — different populations, durations and placebo responses — and the two drugs may eventually be combined rather than chosen between.

Older options still have a place. Pioglitazone and vitamin E have been used in selected patients for years, and the 2024 European guidelines discuss when they may be considered. In a patient with diabetes, the choice of diabetes medicine is itself a liver decision.

Realistic expectations, side effects and who should not take it

The commonest side effects of semaglutide are gastrointestinal — nausea, vomiting, constipation, diarrhoea — and in ESSENCE they were more frequent than with placebo. Most patients settle as the dose is built up gradually. Rapid weight loss itself carries risks, including gallstones and loss of muscle; in cirrhosis-prone patients, muscle loss is exactly what we try to prevent, which is why protein intake and resistance exercise must accompany treatment. Our guide to nutrition and sarcopenia covers this.

Three groups need particular caution. People with cirrhosis are outside the current approval. People with a personal or family history of certain thyroid cancers or specific endocrine syndromes, or a history of pancreatitis, need a careful discussion first. And women who are pregnant or planning pregnancy should not use these drugs. I am deliberately not giving doses or schedules here; those are set by the treating doctor after a full assessment.

Cost and duration matter too. These are long-term treatments, and weight and liver fat tend to return when they stop. Before starting, it is worth agreeing with your hepatologist how response will be judged — usually repeat FibroScan, liver tests and weight at defined intervals — and what happens if there is no benefit.

A practical pathway for patients in India

If you have been told you have fatty liver, the sensible sequence is simple. First, get your fibrosis risk measured: FIB-4 from routine blood tests, then FibroScan if needed. Second, treat the metabolic drivers — weight, diabetes, blood pressure, cholesterol — and stop alcohol, which multiplies damage in a fatty liver. Third, if you have MASH with F2–F3 fibrosis, discuss whether semaglutide is appropriate for you, considering your diabetes treatment, other illnesses, cost and preferences. Fourth, if you already have cirrhosis, your care focuses on complications, liver cancer surveillance and, where needed, transplant assessment; the new drugs are not yet a substitute.

The good news is real. For the first time, Indian patients with scarring fatty liver have an approved medicine with biopsy-proven benefit. The work of losing weight, moving more and controlling diabetes still does most of the heavy lifting. A hepatology assessment can tell you which group you are in.

References

1. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089–2099. PMID 40305708. doi:10.1056/NEJMoa2413258
2. Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–1124. PMID 33185364. doi:10.1056/NEJMoa2028395
3. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299–310. PMID 38856224. doi:10.1056/NEJMoa2401943
4. Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497–509. PMID 38324483. doi:10.1056/NEJMoa2309000
5. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary. Diabetologia. 2024;67(11):2375–2392. PMID 38869512. doi:10.1007/s00125-024-06196-3
6. The Week. Wegovy gets CDSCO approval: can Novo Nordisk’s semaglutide change fatty liver treatment? 17 July 2026. theweek.in